Patricia Wedge

Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: Results from efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) program

Christopher M. O’Connor, Alan B. Miller, John E. Blair et al. · American Heart Journal · 2010 · 235 citations

Medicine, Cardiology, Pharmacotherapy +11

Acute Hemodynamic Effects of Tolvaptan, a Vasopressin V2 Receptor Blocker, in Patients With Symptomatic Heart Failure and Systolic Dysfunction

James E. Udelson, Cesare Orlandi, John Ouyang et al. · Journal of the American College of Cardiology · 2008 · 180 citations

Medicine, Cardiology, Pharmacology +17

Short-Term Effects of Tolvaptan in Patients With Acute Heart Failure and Volume Overload

Marvin A. Konstam, Michael S. Kiernan, A. Bleakley Chandler et al. · Journal of the American College of Cardiology · 2017 · 171 citations

Medicine, Cardiology, Pharmacology +16

Impact of Autonomic Regulation Therapy in Patients with Heart Failure

Marvin A. Konstam, James E. Udelson, Javed Butler et al. · Circulation Heart Failure · 2019 · 66 citations · Full text

Medicine, Cardiology, Internal Medicine +13

Acute Hemodynamic Effects of Tolvaptan, a Vasopressin V2 Receptor Blocker, in Patients with Symptomatic Heart Failure and Systolic Dysfunction: The ECLIPSE International, Multicenter, Randomized, Placebo-controlled Trial

James E. Udelson, Cesare Orlandi, John Ouyang et al. · Journal of Cardiac Failure · 2007 · 10 citations

Medicine, Cardiology, Pharmacology +17